Year: 2024
Type: article
Study design: Observational Study
Abstract: The assessment of sarcoma during clinical practice is primarily based on imaging examination, with no effective biomarkers available. Although it has been established that 1,25(OH) 2 D 3 is abnormally expressed in patients with sarcoma, it remains unclear whether 1,25(OH) 2 D 3 level could be used as an evaluation marker in these patient population. This real-world study investigated 1,25(OH) 2 D 3 level and its association with clinical features in sarcoma patients. Data on 1,25(OH) 2 D 3 , parathyroid hormone, calcium, and calcitonin were collected from 331 patients with sarcoma, while the imaging results and the variation in 1,25(OH) 2 D 3 among 213 patients with sarcoma before and after treatment was further analyzed. We found that the serum 1,25(OH) 2 D 3 level was predominantly decreased in patients with sarcoma, with a mean of 45.68 nmol/L. 1,25(OH) 2 D 3 was significantly correlated with the gender and age of sarcoma patients, with more substantial reductions in women and younger patients. Among sarcoma patients, those with progressive disease exhibited a 7.08 nmol/L (−13.73%) decrease in serum 1,25(OH) 2 D 3 levels compared to baseline, while patients with non-progressive disease showed a 1.11 nmol/L (+ 7.0%) increase. The variation of serum 1,25(OH) 2 D 3 can predict the disease status of patients with sarcoma. Decreased serum 1,25(OH) 2 D 3 levels are indicative of disease progression in sarcoma patients, suggesting its potential for application as a prognostic marker for disease assessment in this patient population.
Source: Discover Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,590
Award: G7978451301
OpenAlex ID: W4401995374